May 25, 2013
(market folly, 12/21/10)
Roberto Mignone's hedge fund Bridger Management just filed a 13G with the SEC regarding shares of Ironwood Pharmaceuticals (IRWD). Due to portfolio activity on December 9th, Bridger has disclosed...(read more)
After market close, Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and partners Forest/Almirall announced positive results from Study ‘302 of linaclotide in IBS-C, the final of the four phase 3 registration trials for the agent (2 in...(read more)
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) rose 21.09% to $11.80 in the pre-market session. IRWD's drug for the treatment of bowel syndrome showed positive results in its phase III testing. Apollo Investment Corporation (NASDAQ:...(read more)
Ironwood Pharmaceuticals (IRWD) Company Overview
There is no analysis for IRWD yet. But you can go to Wikinvest to help create one!